Interview: Paolo Casati – General Manager, Santen Italy
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
In the last decade, Santen has strengthened its presence in Europe and has become a major player in the field of ophthalmology.
Santen is one of the few international companies specialized mainly in ophthalmology. Currently, Santen operates with leading university research centers and key opinion leaders in Europe to better understand diseases and illnesses. Basically, the work will be used to facilitate the diagnosis and management of these conditions.
Santen is committed to protect and improve eyesight, especially eye disorders that require new approaches to treatment.
The company has established its presence in Italy in 2014, in order to reflect its renewed determination to be patient-centric and expand in Europe.
Contact
Piazza Sigmund Freud, 1
20154 Milano
ITALIA
Tel.: +39 02 6200191
Fax: +39 02 62001999
Web: santen.eu/it
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the development of new drugs. The decree…
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector…
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics. The deal, said to…
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases. We are very excited…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community, their core mission of translational medicine and the challenges Italy faces today with the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in academic research. Division director Professor Gianvito Martino discusses the institute’s unique operative…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute, discusses the crucial role the OBT occupies as a link between the industry…
Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of…
Thilo Stadler speaks passionately about Grünenthal’s collaborative partnerships, company goals, and workforce engagement; revealing himself to be someone who truly believes in Grünenthal’s business. You currently hold the position of…
Digitalization, a hot topic throughout the healthcare and life sciences industry, is having a major effect in Italy through more personalized home care for patients, allowing the government to cut costs,…
Regardless of external challenges, the Italian pharmaceutical industry is clearly equipped for success, in terms of physical capital, expertise, and culture. There is a “Made in Italy” element in pharmaceuticals…
See our Cookie Privacy Policy Here
